Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

intega sdn. bhd. - aprepitant -

Сингапур - английский - HSA (Health Sciences Authority)

apex pharma marketing pte. ltd. - fosaprepitant dimeglumine 245.3mg eqv fosaprepitant - injection, powder, lyophilized, for solution - fosaprepitant dimeglumine 245.3mg eqv fosaprepitant 150mg/vial

Соединенные Штаты - английский - NLM (National Library of Medicine)

physicians total care, inc. - aprepitant (unii: 1nf15yr6uy) (aprepitant - unii:1nf15yr6uy) - aprepitant 80 mg - emend, in combination with other antiemetic agents, is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec) [see dosage and administration (2.1)] . emend is indicated for the prevention of postoperative nausea and vomiting [see dosage and administration (2.2)] . emend has not been studied for the treatment of established nausea and vomiting. chronic continuous administration is not recommended [see warnings and precautions (5.5)]. emend is contraindicated in patients who are hypersensitive to any component of the product. emend is a dose-dependent inhibitor of cytochrome p450 isoenzyme 3a4 (cyp3a4). emend should not be used concurrently with pimozide, terfenadine, astemizole, or cisapride. inhibition of cyp3a4 by aprepitant could result in elev

Соединенные Штаты - английский - NLM (National Library of Medicine)

rebel distributors corp - aprepitant (unii: 1nf15yr6uy) (aprepitant - unii:1nf15yr6uy) - aprepitant 40 mg - emend1, in combination with other antiemetic agents, is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (hec) including high-dose cisplatin - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (mec) [see dosage and administration (2.1)] . registered trademark of merck sharp & dohme corp., a subsidiary of merck & co., inc. copyright © 2003, 2005, 2006 merck sharp & dohme corp., a subsidiary of merck & co., inc. all rights reserved emend is indicated for the prevention of postoperative nausea and vomiting [see dosage and administration (2.2)] . emend has not been studied for the treatment of established nausea and vomiting. chronic continuous administration is not recommended [see warnings and precautions (5.5)]. emend is contraindicated in patients who are hypersensitive to any component of the product. emend is a dose-dependen

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

sandoz ltd - aprepitant - oral capsule - 80mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - aprepitant - oral capsule - 80mg

Великобритания - английский - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - aprepitant - oral capsule - 80mg

Австралия - английский - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - aprepitant -

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

alchemy health limited - aprepitant 125mg - capsule - 125 mg - active: aprepitant 125mg excipient: gelatin hypromellose iron oxide red microcrystalline cellulose opacode black s-1-17823 poloxamer 407 purified water sodium laurilsulfate sucrose titanium dioxide - in combination with other antiemetic agents, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy - moderately emetogenic cancer chemotherapy

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

alchemy health limited - aprepitant 40mg - capsule - 40 mg - active: aprepitant 40mg excipient: gelatin hypromellose iron oxide yellow microcrystalline cellulose opacode black s-1-17823 poloxamer 407 purified water sodium laurilsulfate sucrose titanium dioxide - in combination with other antiemetic agents, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: - highly emetogenic cancer chemotherapy - moderately emetogenic cancer chemotherapy